Bionano Genomics Inc
$ 1.16
0.00%
10 Jun - close price
- Market Cap 13,311,000 USD
- Current Price $ 1.16
- High / Low $ 1.19 / 1.15
- Stock P/E N/A
- Book Value 3.32
- EPS -4.46
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.29 %
- ROE -0.74 %
- 52 Week High 5.50
- 52 Week Low 1.06
About
Bionano Genomics, Inc. is a life science instrumentation company in the genome analysis space. The company is headquartered in San Diego, California.
Analyst Target Price
$5.00
Quarterly Earnings
| Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-05-13 | 2026-03-23 | 2025-11-13 | 2025-08-14 | 2025-05-14 | 2025-03-31 | 2024-11-14 | 2024-08-07 | 2024-05-08 | 2024-03-05 | 2023-11-08 | 2023-08-09 |
| Reported EPS | -0.7472 | -0.03 | -1.59 | -1.99 | -10.7888 | -7.73 | -0.2675 | -0.22 | -0.51 | -0.9593 | -1 | -1.24 |
| Estimated EPS | -0.95 | -4.14 | -0.5 | -0.54 | -3.0233 | -6 | -0.21 | -0.42 | -0.64 | -0.87 | -0.97 | -1.03 |
| Surprise | 0.2028 | 4.11 | -1.09 | -1.45 | -7.7655 | -1.73 | -0.0575 | 0.2 | 0.13 | -0.0893 | -0.03 | -0.21 |
| Surprise Percentage | 21.3474% | 99.2754% | -218% | -268.5185% | -256.8551% | -28.8333% | -27.381% | 47.619% | 20.3125% | -10.2644% | -3.0928% | -20.3883% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: BNGO
2026-06-11 12:10:15
Bionano announced that 13 independent studies published in 2026 utilized optical genome mapping (OGM) to analyze 730 samples in reproductive health and prenatal genetics. These studies demonstrated OGM's effectiveness in identifying structural variants often missed by standard methods, uncovering genetic causes for unexplained infertility and recurrent pregnancy loss, and showing high concordance with conventional prenatal diagnostics. The findings highlight OGM's potential to improve genetic resolution and variant interpretation in clinical research settings.
2026-06-11 12:10:15
Bionano Genomics announced 13 studies published in 2026, analyzing 730 samples, demonstrate the utility of optical genome mapping (OGM) for detecting structural variants in reproductive health and prenatal genetic disorders. These studies, conducted by independent research groups, show OGM improving genetic resolution, refining variant interpretation, and detecting complex structural variants missed by standard approaches in conditions like infertility, recurrent pregnancy loss, and prenatal diagnoses. The findings further solidify OGM's role in advancing clinical research in these critical areas.
2026-06-11 12:09:40
Bionano Genomics announced 13 studies published in 2026 demonstrating the utility of optical genome mapping (OGM) in reproductive health and prenatal genetic disorders. These studies, analyzing 730 samples, show OGM's effectiveness in detecting structural variants often missed by standard methods in cases like infertility, recurrent pregnancy loss, and prenatal diagnosis. OGM improved genetic resolution, refined variant interpretation, and identified cryptic and complex structural variants across various research topics and patient cohorts.
2026-06-09 07:39:07
This article details Bionano Genomics' S-8 filing, which is an initial registration statement concerning securities offered to employees through employee benefit plans. The filing was submitted to the SEC.
2026-06-07 13:09:41
BioNano Genomics announced the resignation of its Chief Medical Officer, Alka Chaubey, Ph.D., effective July 5, 2026. This departure may lead to adjustments in the company's clinical strategy. Analysts currently rate BNGO stock as a Buy with a $4.00 price target, though Spark, TipRanks’ AI Analyst, views it as Neutral due to weak financial performance despite improving commercialization metrics.
2026-06-05 19:41:04
Bionano Genomics, Inc. announced that its Chief Medical Officer, Alka Chaubey, Ph.D., submitted her resignation on June 2, 2026, which will become effective on July 5, 2026. The company, traded on Nasdaq under BNGO, reported this material event in an 8-K filing. Albert A. Luderer, Ph.D., currently serves as the Interim Chief Executive Officer.
